** Shares of gene therapy developer bluebird bio BLUE.O fall 1.8% to 36 cents; set to snap a three-day winning streak
** The U.S. FDA says it is weighing the need of regulatory action on BLUE's gene therapy, Skysona, used to treat a rare neurological disorder called cerebral adrenoleukodystrophy
** Additional cases of serious blood cancers reported in patients treated with Skysona, FDA says; therapy's prescribing information already warns of those risks
** FDA advises exploring alternative therapies before using Skysona, considering the risk of blood cancers
** Including session's gains, stock has fallen 73.6% YTD and has been trading below the $1-mark since mid-August
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。